Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2

Toft-Bertelsen et al. describe repurposing of anti-influenza drug amantadine and its derivatives for the treatment of SARS-CoV-2. They show that Amantadine, Emodin and Xanthene show significant blockage of ionchannels formed by SARS-CoV-2 which are crucial for its assembly and pathophysiology.

Guardado en:
Detalles Bibliográficos
Autores principales: Trine Lisberg Toft-Bertelsen, Mads Gravers Jeppesen, Eva Tzortzini, Kai Xue, Karin Giller, Stefan Becker, Amer Mujezinovic, Bo Hjorth Bentzen, Loren B. Andreas, Antonios Kolocouris, Thomas Nitschke Kledal, Mette Marie Rosenkilde
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Acceso en línea:https://doaj.org/article/f7013bc495364bc4bcb0878e0dba41ad
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Toft-Bertelsen et al. describe repurposing of anti-influenza drug amantadine and its derivatives for the treatment of SARS-CoV-2. They show that Amantadine, Emodin and Xanthene show significant blockage of ionchannels formed by SARS-CoV-2 which are crucial for its assembly and pathophysiology.